Tuberculous Meningitis Treatment and Management

Clinical Presentation and Diagnosis

The American Thoracic Society recommends that patients with tuberculous meningitis presenting with symptoms such as fever, headache, and neck stiffness should be promptly evaluated for neurologic signs, including cranial nerve palsies and altered mental status, as these are associated with higher mortality and risk of permanent neurologic sequelae 1
The British Medical Research Council Classification is used to stage the disease, with Stage I being the least severe and Stage III being the most severe, and treatment outcomes vary significantly depending on the stage at presentation 1

The Infectious Diseases Society of America recommends a four-drug regimen consisting of isoniazid, rifampin, pyrazinamide, and ethambutol for the initial 2-month intensive phase, followed by isoniazid and rifampin for an additional 7-10 months, for a total duration of 9-12 months 2, 3
The American Academy of Pediatrics recommends that children with tuberculous meningitis receive isoniazid, rifampin, pyrazinamide, and ethambutol, with dosing adjusted according to weight, and that treatment be continued for at least 9-12 months 2, 3
Adjunctive corticosteroid therapy with dexamethasone or prednisolone is strongly recommended for all patients with tuberculous meningitis, particularly those with decreased level of consciousness, as it reduces mortality, with the American Thoracic Society recommending a dose of 0.4 mg/kg/day of dexamethasone for 3 weeks, then gradually tapered over the following 3 weeks 2, 3, 4

The Centers for Disease Control and Prevention recommend that patients with drug-resistant tuberculous meningitis receive at least 5 effective drugs, including a fluoroquinolone and an injectable agent, and that treatment be individualized based on drug susceptibility testing 5
The World Health Organization recommends that HIV-infected patients with tuberculous meningitis receive careful attention to drug interactions and immune reconstitution inflammatory syndrome, and may require longer treatment courses 2, 3
The American Academy of Neurology recommends that patients with hydrocephalus or tuberculous cerebral abscess receive prompt neurosurgical referral, as these complications can significantly impact treatment outcomes 2

Viral meningitis typically maintains a CSF/plasma glucose ratio >0.36 with normal or slightly low absolute glucose, distinguishing it from tuberculous meningitis 6

The American Thoracic Society recommends starting empiric anti-tubercular therapy immediately when clinical suspicion is supported by CSF findings, as treatment outcomes in TB meningitis depend critically on early initiation before neurologic deterioration 6